SCHEMBL2189965

SCHEMBL2189965

CN1C[C@@H](COc2ccc(C(=O)O)cc2)Oc2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTGIR P43119 14/20 0.64
PTGDR Q13258 2/20 0.60
TBXA2R P21731 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2190959 0.89 PTGIR (0.60) PTGIRPTGDRTBXA2R
SCHEMBL2193189 0.88 PTGIR (0.62) PTGIRPTGDRTBXA2R
SCHEMBL6100655 0.84 PTGIR (0.51) PTGIRPTGDRTBXA2R
SCHEMBL2118089 0.84 PTGDR (0.63) PTGIRPTGDR
SCHEMBL2617067 0.83 PTGIR (0.52) PTGIRPTGDRTBXA2R
SCHEMBL2121180 0.82 PTGIR (0.58) PTGIRPTGDRTBXA2R
SCHEMBL730496 0.82 PTGIR (0.68) PTGIRPTGDR
SCHEMBL5107348 0.82 PTGIR (0.52) PTGIRPTGDRTBXA2R
SCHEMBL2189810 0.82 PTGIR (0.52) PTGIRPTGDRTBXA2R
Acetic Acid SCHEMBL27620819 0.81 PTGIR (0.64) PTGIRPTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357630-A1 Phenylacetic Acid Compound ONO PHARMACEUTICAL CO., LTD. (JP) 2014-12-04 US disclosed
US-8809524-B2 Phenylacetic acid compound ONO PHARMACEUTICAL CO., LTD. (JP) 2014-08-19 US disclosed
US-20130225808-A1 PHENYLACETIC ACID COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-29 US disclosed
US-8476266-B2 Phenylacetic acid compound ONO PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
US-20130028887-A1 PHENYLACETIC ACID COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2013-01-31 US disclosed
US-8318729-B2 Phenylacetic acid compound ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
US-20120094990-A1 PHENYLACETIC ACID COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-19 US disclosed
EP-1486491-B1 CARBOXYLIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2011-07-13 EP disclosed
US-7351705-B2 Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-04-01 US disclosed
US-7291644-B2 Indole derivatives ONO PHARMACEUTICALS CO., LTD. (JP) 2007-11-06 US disclosed
US-7291644-B2 Indole derivatives ONO PHARMACEUTICALS CO., LTD. (JP) 2007-11-06 US disclosed
US-7153852-B2 Indole compounds, process for producing the same and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2006-12-26 US disclosed
US-7135495-B2 Indole derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2006-11-14 US disclosed
US-20060194864-A1 Indole derivatives ONO PHARMACEUTICAL CO., LTD. 2006-08-31 US disclosed
US-20050222216-A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-10-06 US disclosed
US-20050004097-A1 Indole derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-06 US disclosed
US-20050004096-A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-06 US disclosed
EP-1486491-A1 CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-12-15 EP disclosed
EP-1424335-A1 INDOLE DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed
EP-1424325-A1 INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194864-A1 Indole derivatives IDO1, IDO2, PTGIR PTGIR 3/4885PTGDR 6/4885TBXA2R 30/4885
US-20050004097-A1 Indole derivatives IDO1, IDO2, PTGIR PTGIR 3/4885PTGDR 6/4885TBXA2R 30/4885
US-20130225808-A1 PHENYLACETIC ACID COMPOUND PC, PAH, PDHA2 PTGIR 3123/4885PTGDR 1630/4885TBXA2R 2310/4885
US-20050004096-A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient IDO1, IDO2, PTGIR PTGIR 3/4885PTGDR 14/4885TBXA2R 42/4885
US-20120094990-A1 PHENYLACETIC ACID COMPOUND PC, PAH, PDHA2 PTGIR 3123/4885PTGDR 1630/4885TBXA2R 2310/4885
US-20130028887-A1 PHENYLACETIC ACID COMPOUND PC, PAH, PDHA2 PTGIR 3123/4885PTGDR 1630/4885TBXA2R 2310/4885
US-20050222216-A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient UACA, CPA3, HCAR1 PTGIR 30/4885PTGDR 312/4885TBXA2R 226/4885
US-20140357630-A1 Phenylacetic Acid Compound PC, PAH, PDHA2 PTGIR 3123/4885PTGDR 1630/4885TBXA2R 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.